永勝醫療(01612.HK)中期淨利下跌54.4%至4190萬港元
格隆匯8月24日丨永勝醫療(01612.HK)公吿,鑑於2020年的出色表現形成高基數,截至2021年6月30日止6個月收入減少26.2%,符合集團對2019冠狀病毒病疫情影響的預期。與2019年疫情前的數字相比,期間的總收入增加50.4%,而呼吸產品分部則增長97.3%。
公司擁有人應占溢利下跌54.4%至4190萬港元(較2019年同期上升2.1倍)。該減少乃由於期間產品組合改變、產量下跌、人民幣升值及原材料成飆升導致利潤率下跌所致。董事會議決宣派期間中期股息每股2.0港仙(截至2020年6月30日止6個月:零港仙),並將於2021年9月30日(星期四)或前後派付。
骨科支護復康器具分部錄得強勁復甦(上升78.7%),而成像一次性產品分部則穩步增長(上升19.9%)。透過與全球醫療科技企業開展新合作,繼續推動市場份額及長期增長。隨着O2FLO進一步滲透至包括中國、泰國、印度及多個拉丁美洲國家等新市場,其裝機量持續增加。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.